Boston, MA  |   April 8, 2021

Scorpion Therapeutics Appoints Guy Padbury, Ph.D. as Chief Development Officer

BOSTON — April 8, 2021 — Scorpion Therapeutics, Inc., a next-generation precision oncology company, today announced the appointment of Guy Padbury, Ph.D. as Chief Development Officer....

February 25, 2021

Scorpion Therapeutics Announces Leadership Change

– Board Appoints Adam Friedman, M.D., Ph.D., as Interim CEO –  Scorpion Therapeutics announced that Adam Friedman, M.D., Ph.D., has been appointed Chief Executive Officer on an interim basis. The Board of Directors is currently evaluating...

January 13, 2021

J.P. Morgan 39th Annual Healthcare Conference

Fierce Biotech  |   January 12, 2021

Scorpion Therapeutics strikes major $162M funding round for ‘precision oncology 2.0’

Less than three months after breaking cover with an impressive $102 million series A, Scorpion has whipped up another major funding round, nabbing $162 million for its next-gen cancer drugs.

Boston Globe  |   January 12, 2021

With biotech funding at ‘all-time high,’ Scorpion scoops up $162 million

Just over two months after announcing its debut with $108 million in funding, Boston startup Scorpion Therapeutics said Thursday it has raised an even larger amount of venture capital.

Endpoints News  |   January 12, 2021

Gary Glick, Keith Flaherty now have $270M to realize their vision for Precision Oncology 2.0 — we’ll just have to wait for the details

Whatever investors have peeped about Gary Glick and Keith Flaherty’s game plan to bring about Precision Oncology 2.0, it’s good enough for a $162 million infusion into Scorpion Therapeutics just weeks after its $108 million Series A.

January 7, 2021

Scorpion Therapeutics Announces Oversubscribed $162 Million Series B Financing

—  Proceeds support advancement of Precision Oncology 2.0 drug-hunting engine and first wave of therapeutic candidates — — Company management to present at 39th Annual J.P....

Fierce Biotech  |   October 26, 2020

Scorpion Therapeutics debuts with $108M to ‘put the sting in cancer’

When Gary Glick, Ph.D., left the CEO post at IFM Therapeutics, he didn’t know what was next. But he soon found himself on a plane with Loxo Oncology co-founder Keith Flaherty, and they got to talking about how they could “expand the boundaries of targeted oncology.”

Boston Globe  |   October 26, 2020

Scorpion, seeking to develop ‘precision medicine’ drugs for cancer, debuts with $108m in funding

Gary Glick is chief executive of Scorpion Therapeutics. Courtesy of Scorpion Therapeutics.  Scorpion Therapeutics is the latest biotech to debut in Boston, with $108 million in venture capital and a roster of local industry veterans.

Endpoints News  |   October 26, 2020

What can a biotech entrepreneur and a top scientist come up with on a couple of shared flights? Well…

Just weeks before the pandemic hit the states, Gary Glick and Keith Flaherty had a chance to spend 12 hours together, talking craft and trade on...